Adverse events63

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 63

Type	Event	Organ system	Group	Affected	At risk	Events
other	Abdominal pain	Gastrointestinal disorders	Treatment (Sargramostim and Dinutuximab)	8	39	8
other	Diarrhea	Gastrointestinal disorders	Treatment (Sargramostim and Dinutuximab)	4	39	4
other	Nausea	Gastrointestinal disorders	Treatment (Sargramostim and Dinutuximab)	2	39	2
other	Vomiting	Gastrointestinal disorders	Treatment (Sargramostim and Dinutuximab)	1	39	1
other	Fever	General disorders	Treatment (Sargramostim and Dinutuximab)	2	39	2
other	Non-cardiac chest pain	General disorders	Treatment (Sargramostim and Dinutuximab)	1	39	1
other	Pain	General disorders	Treatment (Sargramostim and Dinutuximab)	7	39	7
other	Allergic reaction	Immune system disorders	Treatment (Sargramostim and Dinutuximab)	5	39	5
other	Cytokine release syndrome	Immune system disorders	Treatment (Sargramostim and Dinutuximab)	1	39	1
other	Serum sickness	Immune system disorders	Treatment (Sargramostim and Dinutuximab)	1	39	1
other	Catheter related infection	Infections and infestations	Treatment (Sargramostim and Dinutuximab)	1	39	1
other	Infections and infestations - Other, specify	Infections and infestations	Treatment (Sargramostim and Dinutuximab)	1	39	1
other	Skin infection	Infections and infestations	Treatment (Sargramostim and Dinutuximab)	1	39	1
other	Alanine aminotransferase increased	Investigations	Treatment (Sargramostim and Dinutuximab)	2	39	2
other	GGT increased	Investigations	Treatment (Sargramostim and Dinutuximab)	2	39	2
other	Lymphocyte count decreased	Investigations	Treatment (Sargramostim and Dinutuximab)	3	39	3
other	Neutrophil count decreased	Investigations	Treatment (Sargramostim and Dinutuximab)	2	39	2
other	Platelet count decreased	Investigations	Treatment (Sargramostim and Dinutuximab)	1	39	1
other	Urine output decreased	Investigations	Treatment (Sargramostim and Dinutuximab)	1	39	1
other	White blood cell decreased	Investigations	Treatment (Sargramostim and Dinutuximab)	1	39	1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02484443/events

API reference For AI assistants

Adverse events63

Sources 3

Read this list from software.